Efficacy of MEDI0618, a pH-dependent monoclonal antibody targeting PAR2, in preclinical models of migraine - Summary - MDSpire

Efficacy of MEDI0618, a pH-dependent monoclonal antibody targeting PAR2, in preclinical models of migraine

  • By

  • Caroline M Kopruszinski

  • John E Linley

  • Peter Thornton

  • Alison S Walker

  • Philip Newton

  • Sadhana Podichetty

  • Radhey Hemendra Ruparel

  • Luiz Henrique Moreira de Souza

  • Edita Navratilova

  • Guy Meno-Tetang

  • Ian Gurrell

  • David W Dodick

  • Claire Dobson

  • Tharani Chessell

  • Frank Porreca

  • Iain Chessell

  • February 28, 2025

  • 0 min

Share

Objective:

To evaluate the efficacy of MEDI0618, a monoclonal antibody targeting PAR2, in preclinical models of migraine and post-traumatic headache, highlighting the differences between these conditions.

Key Findings:
  • MEDI0618 specifically binds to human PAR2 and prevents calcium influx in relevant cell types, indicating its potential as a targeted therapy.
  • It effectively reduced migraine-like pain in various preclinical models, including those independent of CGRP, suggesting a broader therapeutic application.
  • MEDI0618 did not prevent post-traumatic headache measures following mild traumatic brain injury, indicating a limitation in its efficacy.
Interpretation:

MEDI0618 shows promise as a novel therapy for migraine prevention, targeting both CGRP-dependent and independent pathways, which may address unmet needs in migraine treatment.

Limitations:
  • The study was conducted in preclinical models, which may not fully replicate human migraine pathology, potentially limiting the applicability of results.
  • MEDI0618's efficacy in chronic migraine conditions and long-term safety were not assessed, raising questions about its use in diverse patient populations.
Conclusion:

MEDI0618 is a potent PAR2 inhibitor with potential for migraine prevention, warranting further clinical investigation.

Original Source(s)

Efficacy of MEDI0618, a pH-dependent monoclonal antibody targeting PAR2, in preclinical models of migraine

  • by Caroline M Kopruszinski, John E Linley, Peter Thornton, Alison S Walker, Philip Newton, Sadhana Podichetty, Radhey Hemendra Ruparel, Luiz Henrique Moreira de Souza, Edita Navratilova, Guy Meno-Tetang, Ian Gurrell, David W Dodick, Claire Dobson, Tharani Chessell, Frank Porreca, Iain Chessell

  • February 28, 2025

Related Content

Evaluation of the Safety and Effectiveness of Calcitonin Gene-Related Peptide Antagonists in Treating Cluster Headaches: A Systematic Review and Meta-Analysis

Cognitive Impairment Associated with Mild to Moderate Migraine Episodes: Possible Effects on Workplace Attendance

NPs Top US Jobs List Again

The nurse practitioner profession claims the No. 1 spot across three categories in the U.S. News & World Report 2026 Best Jobs rankings for the third consecutive year.